당뇨병성 황반부종(DME) : 시장 인사이트, 역학 및 시장 예측(2036년)

Diabetic Macular Edema (DME) Insights and Trends

• According to DelveInsight estimates, in 2025, the United States accounted for the highest DME market size, i.e., approximately USD 2,200 million, although recent analyses suggest potential upside driven by increasing adoption of novel and targeted therapies.
• In 2025, the market size of DME across the 7MM was approximately USD 4,000 million, reflecting a substantial commercial opportunity driven by a high disease burden and ongoing demand for anti-VEGF and emerging therapies.
• DME develops as a complication of Diabetic Retinopathy, resulting from damage to retinal blood vessels that leads to fluid leakage and macular swelling. DR is a leading cause of vision loss among working-age individuals worldwide.
• Owing to the higher patient pool and higher treatment cost, according to the estimates, the United States had the highest market size in DME, i.e., ~60% of the total market size of DME in the 7MM, in 2025, followed by Germany and Japan.
• Management of DME primarily involves anti-VEGF therapies, corticosteroids, and laser photocoagulation. Nonsteroidal anti-inflammatory drugs (NSAIDs) in eye-drop form are occasionally used around cataract surgery to help prevent postoperative macular edema.
• In July 2025, Samsung Bioepis signed a commercialization deal with Harrow for its US ophthalmology biosimilars portfolio, which includes aflibercept-yszy (OPUVIZ), a biosimilar to EYLEA. The US FDA approved OPUVIZ in May 2024 for treating DME and other retinal diseases. After Biogen transfers commercial rights by the end of 2025, Harrow will take over full commercialization duties. This positions OPUVIZ as a more affordable option in the DME market, likely boosting patient access and heightening competition in the anti-VEGF category.
• The DME treatment landscape includes several FDA-approved anti-VEGF therapies such as LUCENTIS (ranibizumab) and EYLEA (aflibercept). In January 2022, faricimab-svoa (VABYSMO) became the first dual inhibitor of VEGF-A and Ang-2, offering extended dosing benefits. Brolucizumab-dbll (BEOVU) was approved in June 2022, providing similar efficacy to aflibercept with longer dosing intervals. Most recently, in February 2025, ranibizumab injection (SUSVIMO) was approved as a long-acting implantable treatment option, further reducing treatment burden.
• Growth of the Diabetic Macular Edema market is driven by rising diabetes prevalence, improved diagnosis and screening, increased adoption of anti-VEGF and dual-pathway therapies, and the emergence of long-acting innovative treatments.
• DME is diagnosed using clinical examination and OCT imaging, with classification into center-involved (CI-DME) when the fovea is affected, and non-center-involved (NCI-DME) when it is spared.

DelveInsight's 'Diabetic Macular Edema (DME) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the diabetic macular edema, historical and forecasted epidemiology, as well as the diabetic macular edema market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Diabetic Macular Edema (DME) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates diabetic macular edema patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in diabetic macular edema and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Diabetic Macular Edema (DME) Market

Rising Burden and Risk Factors in Diabetic Macular Edema (DME)

DME incidence is increasing globally, primarily driven by the rising prevalence of Diabetes Mellitus and associated complications. Poor glycemic control, longer disease duration, hypertension, and obesity significantly increase the risk of developing DME. Additionally, the growing aging population and increasing incidence of type 2 diabetes are expanding the patient pool, thereby driving demand for effective ophthalmic therapies.

Advancements in Multimodal Treatment Approaches

The standard of care for DME has evolved significantly, with treatment options including anti-VEGF therapy, corticosteroids, and laser photocoagulation. The integration of pharmacologic therapies with advanced imaging techniques such as optical coherence tomography (OCT) has improved early diagnosis and treatment monitoring. Personalized treatment regimens based on disease severity and patient response are further enhancing clinical outcomes and supporting market growth.

Anti-VEGF Dominance:

The introduction of anti-VEGF and targeted therapies has transformed the management of DME by addressing vascular leakage and improving visual outcomes. Agents such as EYLEA, LUCENTIS, BEOVU, and VABYSMO are widely used as first-line treatments, driving market growth through strong clinical efficacy and high adoption rates

Emerging Diabetic Macular Edema Competitive Landscape

The DME pipeline is expanding with innovative therapies targeting novel pathways beyond VEGF. Emerging agents include gene therapies, sustained delivery anti-VEGF formulations, and novel biologics aimed at improving durability and efficacy. These advancements are expected to address unmet needs such as frequent dosing and suboptimal response, thereby enhancing the treatment landscape and driving market growth during the forecast period.

Diabetic Macular Edema Understanding and Treatment Algorithm

Diabetic Macular Edema Overview and Diagnosis

DME is a vision-threatening complication of Diabetes Mellitus and a manifestation of Diabetic Retinopathy. It is characterized by the accumulation of fluid in the macula due to leakage from damaged retinal blood vessels, leading to retinal thickening and impairment of central vision. Chronic hyperglycemia disrupts the blood-retinal barrier, increasing vascular permeability and promoting fluid buildup in the macula. DME is a leading cause of vision loss among working-age adults globally. The disease burden continues to rise alongside increasing diabetes prevalence, driven by aging populations, sedentary lifestyles, and obesity, underscoring the need for early detection and effective management strategies.

Diabetic Macular Edema Diagnosis

Diagnosis of DME involves a combination of clinical evaluation and advanced retinal imaging. Patients may present with blurred or distorted central vision, although early stages can be asymptomatic, making routine screening essential in individuals with Diabetes Mellitus. Fundus examination is typically the initial step to detect retinal abnormalities, while optical coherence tomography (OCT) serves as the gold standard for confirming retinal thickening and fluid accumulation. Fluorescein angiography may be used to evaluate vascular leakage and retinal perfusion.

DME is further classified into center-involved (CI-DME) when the fovea is affected, and non-center-involved (NCI-DME) when the central macula is spared. Advances in imaging and biomarkers are enhancing diagnostic accuracy and enabling better monitoring of disease progression and treatment response.

Diabetic Macular Edema (DME) Treatment

The treatment of DME involves a multidisciplinary and stepwise approach, primarily aimed at reducing retinal swelling, preserving vision, and preventing disease progression. The current standard of care is dominated by intravitreal anti-VEGF therapies, which are considered the first-line treatment due to their strong efficacy in improving visual acuity and reducing macular thickness. Commonly used agents include Aflibercept (EYLEA), Ranibizumab (LUCENTIS), and Bevacizumab (AVASTIN), which act by inhibiting VEGF and decreasing vascular permeability. While bevacizumab is not specifically approved for DME, it is widely used off-label due to its cost-effectiveness.

Systemic and localized pharmacologic therapies play a central role in disease management, as medications are delivered directly into the eye (intravitreal) to target retinal pathology. The main classes of therapies include anti-VEGF agents, corticosteroids, and adjunctive treatments. Among these, anti-VEGF therapies remain the backbone, while newer innovations such as Ranibizumab implant (SUSVIMO) provide sustained drug delivery, significantly reducing treatment burden and injection frequency compared to conventional regimens.

Corticosteroids are typically used as second-line therapies, especially in patients with inadequate response to anti-VEGF agents. These include intravitreal implants such as Dexamethasone implant and Fluocinolone implant, which help reduce inflammation and vascular leakage. However, their use may be associated with side effects such as increased intraocular pressure and cataracts, limiting long-term use in some patients.

Laser photocoagulation remains an adjunctive treatment option, particularly in selected cases. Advances in laser technologies, including subthreshold micro pulse and navigated laser systems, have improved precision and safety, minimizing damage to surrounding retinal tissue. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) may be used in specific situations, such as perioperative management around cataract surgery to prevent macular edema. Overall, the DME treatment landscape is evolving toward long-acting therapies, reduced injection frequency, and improved patient compliance, with anti-VEGF agents continuing to dominate, while sustained delivery systems, corticosteroid implants, and adjunctive therapies contribute to a more personalized and effective treatment approach.

Diabetic Macular Edema (DME) Unmet Needs

The section "unmet needs of diabetic macular edema" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Limited Durability of Existing Anti-VEGF Therapies
• Treatment-Related Adverse Effects (e.g., increased intraocular pressure, cataracts)
• Lack of Effective Therapies for Anti-VEGF Non-Responders
• High Cost of Long-Term Treatment and Access Barriers
• Need for Long-Acting and Sustained Drug Delivery Options
• Limited Role of Biomarker-Driven or Personalized Therapies
• Delayed Diagnosis Due to Asymptomatic Early Stages
• Limited Patient Awareness and Screening Compliance
• Disease Recurrence and Need for Continuous Monitoring and others...

Comprehensive unmet needs insights in DME and their strategic implications are provided in the full report.

Diabetic Macular Edema (DME) Epidemiology

Key Findings from Diabetic Macular Edema Epidemiological (DME) Analysis and Forecast

• According to DelveInsight's estimates, the total diagnosed prevalence cases of DME in the 7MM were approximately 900,000 in 2025.
• It has been observed that the prevalence of DME is higher (~300,000) in males as compared to females (~210,000) in the United States.
• Among EU4 and the UK, Germany accounted for the highest number of DME cases, followed by France, whereas Spain had the lowest number of cases in 2025.
• In 2025, Central-involved DME was the most prevalent subgroup in Japan, followed by Non-center-involved DME.
• In the United States, among all the age groups, 45-64 years accounted for the highest number of DME cases, i.e., around ~2,24,000, in 2025, followed by the age group>= 75 years (~2,20,000).
• In 2025, Japan accounted for approximately 10% of the total diagnosed prevalent cases of Diabetic Macular Edema across the 7MM.

Diabetic Macular Edema (DME) Drug Chapters & Competitive Analysis

The DME drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the diabetic macular edema treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the DME therapeutics market.

Approved Therapies for Diabetic Macular Edema

Aflibercept (EYLEA): Regeneron Pharmaceuticals/Bayer

EYLEA is a recombinant fusion protein that combines VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. It binds VEGF-A, VEGF-B, and Placental Growth Factor (PGF), effectively acting as a VEGF trap. This mechanism blocks abnormal blood vessel growth in the retina. EYLEA was approved by the US FDA in July 2014 for the treatment of DME.

Ranibizumab (LUCENTIS): Genentech

LUCENTIS is a monoclonal antibody fragment derived from the same parent antibody as bevacizumab. It inhibits angiogenesis and is approved for several retinal diseases. LUCENTIS received US FDA approval in 2012 for DME. Genentech markets it in the US, while Novartis handles markets outside the US.

Diabetic Macular Edema (DME) Pipeline Analysis

OCS-01: Oculis

OCS-01 is a high-concentration dexamethasone eye drop for DME. It is developed using the Optireach solubilizing technology, a proprietary platform that enables the formulation of drugs as a topical eye drop treatment with improved solubility, higher concentration, longer residence time, and enhanced bioavailability in eye tissues, including the retina. If approved in DME, it has the potential to provide a new and potentially the FIRST non-invasive eye drop option for patients. OCS-01 eye drops completed Stage 1 of the DIAMOND Phase III trial in DME with 148 patients randomized. Top-line results show a significant increase in visual gains, a higher percentage of patients achieving >=15-letter improvement in BCVA, and a reduction of retinal edema, all with robust statistical significance, reaffirming the effect observed in the Phase II trial.

• In September 2025, Oculis presented expanded data analysis from the Phase III Stage 1 DIAMOND program for OCS-01 eye drops in DME at the 25th European Society of Retina Specialists (EURETINA) Congress.
• In April 2025, Oculis announced that it had completed enrollment in both Phase III DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. Topline data from both Phase III trials is expected in the second quarter of 2026, with NDA submission to the US FDA for OCS-01 for the treatment of DME planned for the fourth quarter of 2026.

Diabetic Macular Edema (DME) Key Players, Market Leaders, and Emerging Companies

• Regeneron Pharmaceuticals/Bayer
• Genentech
• Bayer
• Sandoz
• Roche
• Novartis
• Oculis
• Merck, and others

Diabetic Macular Edema (DME) Drug Updates

• In April 2026, Regeneron Pharmaceuticals announced that the US FDA had approved the extension of dosing intervals for EYLEA up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and DME following one year of successful response based on visual and anatomic outcomes.
• In February 2026, Sandoz announced that the US FDA had approved an expanded label for ENZEEVU, to include multiple retinal indications. ENZEEVU was originally approved by the FDA for the treatment of neovascular wAMD. The most recent approval expands the ENZEEVU label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and DME, along with the previously approved indication of nAMD.
• In February 2025, Roche received US FDA approval for Ranibizumab Implant for DME, marking the first long-acting ocular implant that maintains vision with significantly fewer treatments compared to monthly injections.

Drug Class Insights

Diabetic Macular Edema (DME) Market Outlook

DME is a major complication of Diabetes Mellitus and remains a leading cause of vision impairment among working-age populations. From a market perspective, patients with chronic and center-involved DME contribute the highest burden due to the need for long-term, repeated treatments and continuous monitoring, particularly in regions with rising diabetes prevalence.

The DME market is primarily driven by the increasing adoption of intravitreal therapies and advancements in retinal imaging technologies such as OCT, enabling early diagnosis and treatment monitoring. The treatment paradigm is largely centered on anti-VEGF therapies, with agents such as Aflibercept, Ranibizumab, Brolucizumab (BEOVU), and Faricimab (VABYSMO) forming the backbone of therapy, offering significant improvements in visual acuity and retinal outcomes.

The treatment landscape is evolving with the introduction of long-acting and sustained delivery systems, such as Ranibizumab implant, which reduces injection frequency and improves patient adherence. Additionally, the entry of biosimilars such as aflibercept-abzv (ENZEEVU) and Aflibercept-yszy is expected to increase competition, improve affordability, and expand patient access, thereby influencing market dynamics significantly. Despite these advancements, the DME market continues to face challenges, including high treatment burden due to frequent intravitreal injections, variability in patient response, and safety concerns associated with certain therapies. Additionally, a subset of patients remains inadequately responsive to anti-VEGF therapies, highlighting the need for alternative mechanisms and more durable treatment options.

Looking ahead, the DME market is expected to witness continued innovation with emerging therapies such as OCS-01, RG6351, and Restoret, which aim to address unmet needs through novel mechanisms, non-invasive delivery approaches, and improved durability. Collectively, these advancements, along with increasing uptake of biosimilars and long-acting therapies, are expected to reshape the DME treatment landscape and drive market growth during the forecast period.

• According to estimates, the United States accounted for the largest market size of DME among the 7MM, at approximately USD 2,200 million in 2025.
• Among the EU4 and the UK, Germany accounted for the highest market size in 2025, followed by Italy, while France recorded the lowest.
• The DME market is driven by rising disease prevalence, dominance of anti-VEGF therapies, and a shift toward long-acting, cost-effective treatment options.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Diabetic Macular Edema (DME) (2022-2036 Forecast)

The existing DME treatment landscape is primarily dominated by therapeutic classes such as anti-VEGF agents, corticosteroids, and emerging targeted therapies. Among anti-VEGF therapies, Aflibercept plays a key role by binding VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting vascular permeability and reducing macular edema. Similarly, Ranibizumab and Brolucizumab (BEOVU) act by targeting VEGF-A, effectively reducing retinal swelling and improving visual outcomes. The newer bispecific antibody Faricimab (VABYSMO) further enhances efficacy by simultaneously targeting VEGF-A and Ang-2, leading to improved vascular stability and extended treatment durability.

Moving to corticosteroids and adjunctive therapies, these agents are primarily used in patients who show inadequate response to anti-VEGF treatments. They act by reducing inflammation and vascular leakage, although their use is often limited by side effects such as increased intraocular pressure and cataract formation. In parallel, laser photocoagulation continues to play a supportive role in selected patients, with advancements enabling greater precision and reduced retinal damage.

Long-acting and sustained delivery therapies are increasingly shaping the DME treatment paradigm. Innovations such as Ranibizumab implant provide continuous intraocular drug delivery, significantly reducing the frequency of intravitreal injections and improving patient adherence. Additionally, the introduction of biosimilars such as Enzeevu and Aflibercept-yszy is enhancing affordability, accessibility, and market competition, while maintaining comparable efficacy to originator biologics.

Targeted and novel mechanism-based therapies are also gaining traction, particularly for patients who are non-responsive to conventional anti-VEGF agents. Emerging therapies such as RG6351 aim to improve vascular stability via Tie-2 pathway activation, while OCS-01 represents a non-invasive treatment approach targeting inflammation. Additionally, investigational agents such as Restoret are being developed to address disease mechanisms beyond VEGF inhibition. Looking ahead, the DME treatment landscape is expected to evolve significantly with the emergence of next-generation therapies focused on durability, reduced treatment burden, and novel pathways. Over the 2022-2036 forecast period, these innovations, including sustained-release systems, biosimilars, and non-VEGF targeted therapies, are anticipated to improve patient outcomes, expand access, and drive a shift toward more personalized and long-acting treatment approaches in diabetic macular edema.

Diabetic Macular Edema (DME) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the diabetic macular edema market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in DME is expected to vary across anti-VEGF agents, corticosteroids, sustained-delivery systems, and emerging targeted therapies. Established treatments such as Aflibercept and Ranibizumab continue to dominate frontline management due to their proven efficacy in improving visual acuity and widespread clinical adoption. In addition, newer anti-VEGF agents such as Brolucizumab (BEOVU) and Faricimab (VABYSMO) are witnessing increasing uptake, driven by their enhanced durability and reduced treatment frequency.

Long-acting delivery systems are also gaining traction, with Ranibizumab implant expected to see gradual but significant adoption due to its ability to reduce injection burden and improve patient compliance. At the same time, the introduction of biosimilars such as ENZEEVU and Aflibercept-yszy is anticipated to accelerate uptake by improving affordability and expanding patient access, particularly in cost-sensitive markets.

On the other hand, emerging therapies, including OCS-01, RG6351, and Restoret, are expected to witness gradual but progressive uptake over the forecast period. Their adoption will largely depend on clinical trial success, regulatory approvals, and their ability to address unmet needs such as non-response to anti-VEGF therapies and high treatment burden. Furthermore, therapies offering novel mechanisms of action or non-invasive delivery approaches are likely to gain attention in specific patient subsets.

As clinical evidence continues to evolve and the focus shifts toward long-acting, cost-effective, and personalized treatment strategies, next-generation therapies are anticipated to gain traction, particularly among patients requiring reduced injection frequency or those inadequately responsive to current therapies, thereby reshaping the overall DME treatment landscape.

Diabetic Macular Edema (DME) Therapies Price Scenario & Trends

Pricing and analogue assessment of DME therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Diabetic Macular Edema (DME) Drugs

The wholesale acquisition cost (WAC) of Aflibercept (EYLEA) is approximately USD 1,800-1,900 per intravitreal injection, resulting in an estimated annual cost of USD 10,000-15,000 depending on dosing frequency and treatment duration.

Further details are provided in the final report....

Industry Experts and Physician Views for Diabetic Macular Edema (DME)

To keep up with Diabetic Macular Edema market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the diabetic macular edema emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in DME, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Chiba University Graduate School of Medicine and the University of Pennsylvania, etc. were contacted. Their opinion helps understand and validate current and emerging DME therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in DME.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Diabetic Macular Edema, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of diabetic macular edema, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the diabetic macular edema market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM diabetic macular edema market.

Report Insights

• Diabetic Macular Edema (DME) Patient Population Forecast
• Diabetic Macular Edema (DME) Therapeutics Market Size
• Diabetic Macular Edema (DME) Pipeline Analysis
• Diabetic Macular Edema (DME) Market Size and Trends
• Diabetic Macular Edema (DME) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Diabetic Macular Edema (DME) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Diabetic Macular Edema (DME) Treatment Addressable Market (TAM)
• Diabetic Macular Edema (DME) Competitive Landscape
• Diabetic Macular Edema (DME) Major Companies Insights
• Diabetic Macular Edema (DME) Price Trends and Analogue Assessment
• Diabetic Macular Edema (DME) Therapies Drug Adoption/Uptake
• Diabetic Macular Edema (DME) Therapies Peak Patient Share analysis

Report Assessment

• Diabetic Macular Edema (DME) Current Treatment Practices
• Diabetic Macular Edema (DME) Unmet Needs
• Diabetic Macular Edema (DME) Clinical Development Analysis
• Diabetic Macular Edema (DME) Emerging Drugs Product Profiles
• Diabetic Macular Edema (DME) Market Attractiveness
• Diabetic Macular Edema (DME) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the diabetic macular edema market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of diabetic macular edema?
• What are the disease risks, burdens, and unmet needs of diabetic macular edema? What will be the growth opportunities across the 7MM concerning the patient population with diabetic macular edema?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of diabetic macular edema? What are the current guidelines for treating diabetic macular edema in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the diabetic macular edema market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Diabetic Macular Edema (DME) Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of Diabetic Macular Edema (DME) by Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of Diabetic Macular Edema (DME) by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Diabetic Macular Edema (DME)

• 7.1. Introduction
• 7.2. Types
• 7.3. Symptoms
• 7.4. Causes
• 7.5. Pathophysiology
• 7.6. Diagnosis
• 7.7. Treatment
  • 7.7.1. Treatment Guidelines

8. Epidemiology and Patient Population of Diabetic Macular Edema (DME)

• 8.1. Key Findings
• 8.2. Assumptions and Rationale
• 8.3. Total Prevalent Cases of DME in the 7MM
• 8.4. Total Diagnosed Prevalent Cases of DME in the 7MM
• 8.5. The United States
  • 8.5.1. Total Prevalent Cases of DME in the United States
  • 8.5.2. Total Diagnosed Prevalent cases of DME in the United States
  • 8.5.3. Gender-specific Diagnosed Prevalent Cases of DME in the United States
  • 8.5.4. Age-specific Diagnosed Prevalent Cases of DME in the United States
  • 8.5.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States
  • 8.5.6. Total Treated Cases of DME in the United States
• 8.6. EU4 and the UK
  • 8.6.1. Total Prevalent Cases of DME in EU4 and the UK
  • 8.6.2. Total Diagnosed Prevalent cases of DME in EU4 and the UK
  • 8.6.3. Gender-specific Diagnosed Prevalent Cases of DME in EU4 and the UK
  • 8.6.4. Age-specific Diagnosed Prevalent Cases of DME in EU4 and the UK
  • 8.6.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in EU4 and the UK
  • 8.6.6. Total Treated Cases of DME in EU4 and the UK
• 8.7. Japan
  • 8.7.1. Total Prevalent Cases of DME in Japan
  • 8.7.2. Total Diagnosed Prevalent cases of DME in Japan
  • 8.7.3. Gender-specific Diagnosed Prevalent Cases of DME in Japan
  • 8.7.4. Age-specific Diagnosed Prevalent Cases of DME in Japan
  • 8.7.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan
  • 8.7.6. Total Treated Cases of DME in Japan

9. Patient Journey of Diabetic Macular Edema (DME)

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Diabetic Macular Edema
• 10.2. Aflibercept (EYLEA): Regeneron Pharmaceuticals/Bayer
  • 10.2.1. Drug Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Clinical Development
    • 10.2.5.1. Clinical Trial Information
  • 10.2.6. Analyst Views
• 10.3. Ranibizumab (LUCENTIS): Genentech
  • 10.3.1. Drug Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Summary of Pivotal Trials
  • 10.3.5. Clinical Development
    • 10.3.5.1. Clinical Trial Information
  • 10.3.6. Analyst Views

11. Emerging Drugs

• 11.1. Emerging Competitive Landscape of Diabetic Macular Edema
• 11.2. OCS-01: Oculis
  • 11.2.1. Drug Description
  • 11.2.2. Other Developmental Activity
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trials Information
  • 11.2.4. Analyst Views
• 11.3. Restoret (MK-3000, formerly EYE103): Merck
  • 11.3.1. Drug Description
  • 11.3.2. Clinical Development
    • 11.3.2.1. Clinical Trial Information
  • 11.3.3. Safety and Efficacy
  • 11.3.4. Analyst Views

12. Diabetic Macular Edema (DME): 7MM Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Diabetic Macular Edema
• 12.3. Key Market Forecast Assumptions
  • 12.3.1. Cost Assumptions
  • 12.3.2. Pricing Trends
  • 12.3.3. Analogue Assessment
  • 12.3.4. Launch Year and Therapy Uptakes
• 12.4. Conjoint Analysis of Diabetic Macular Edema
• 12.5. Total Market Size of Diabetic Macular Edema in the 7MM
• 12.6. Total Market Size of Diabetic Macular Edema by Therapies in the 7MM
• 12.7. The United States
  • 12.7.1. Total Market Size of Diabetic Macular Edema in the United States
  • 12.7.2. Total Market Size of Diabetic Macular Edema by Therapies in the United States
• 12.8. EU4 and the UK
  • 12.8.1. Total Market Size of Diabetic Macular Edema in EU4 and the UK
  • 12.8.2. Total Market Size of Diabetic Macular Edema by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of Diabetic Macular Edema in Japan
  • 12.9.2. Total Market Size of Diabetic Macular Edema by Therapies in Japan

13. Unmet Needs of Diabetic Macular Edema (DME)

14. SWOT Analysis of Diabetic Macular Edema (DME)

15. KOL Views of Diabetic Macular Edema (DME)

16. Market Access and Reimbursement of Diabetic Macular Edema (DME)

• 16.1. The United States
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of Diabetic Macular Edema Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight